Gilead los­es yet an­oth­er ex­ec­u­tive as CFO Wash­ing­ton joins ex­o­dus, jump­ing to Al­pha­bet board

Ahead of re­leas­ing its first-quar­ter re­sults on Thurs­day, Gilead dis­closed yet an­oth­er se­nior ex­ec­u­tive de­par­ture: long­time CFO Robin Wash­ing­ton, who un­veiled plans to ex­it come March 2020. In par­al­lel with the drug­mak­er’s an­nounce­ment on Tues­day, Google’s par­ent com­pa­ny Al­pha­bet un­veiled Wash­ing­ton was set to serve on its board.

The spate of de­par­tures at Gilead — which is look­ing to rein­vig­o­rate its growth en­gine as its once-ti­tan­ic hep C fran­chise wanes — are be­gin­ning to re­sem­ble a mass ex­o­dus. Days af­ter new chief Daniel O’Day start­ed his run at the com­pa­ny’s helm last month, ex­ec­u­tive vice pres­i­dent of on­col­o­gy Alessan­dro Ri­va re­vealed he was off to run a US-based biotech spin­off from In­dia’s Glen­mark. His ex­it was pre­ced­ed by CEO John Mil­li­gan, chair­man John Mar­tin and R&D chief Nor­bert Bischof­berg­er. Bischof­berg­er’s re­place­ment, An­drew Cheng, stepped up as chief med­ical of­fi­cer at Gilead, on­ly to leave to run his own biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER